Bluebird Bio (BLUE) said Wednesday its board reaffirmed its support for its planned acquisition by Carlyle (CG) and SK Capital as Ayrmid has not sent a binding or fully financed offer after three weeks of engagement, including a timeline extension.
Bluebird said Ayrmid's proposal remained "highly conditional" even after it engaged with Ayrmid on two occasions.
The company said it has recommended that all stockholders tender by May 2 into the current agreement with Carlyle and SK Capital.
Under the deal announced in February, Bluebird agreed to be acquired and taken private by funds managed by Carlyle and SK Capital for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.
Shares of Bluebird were down more than 6% in recent trading Wednesday.
Price: 4.19, Change: -0.28, Percent Change: -6.26
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。